These results are preliminary, observed in animal or cellular models. Research in humans is still limited.

CBD products are not medicines and should not be used to diagnose, treat, or cure diseases.

CBD is the only cannabinoid with randomized human clinical trials and regulatory approval.

Clinical studies have shown significant reductions in seizure frequency in children and adults with drug-resistant epilepsy, particularly in specific neurological syndromes.

Human clinical trials indicate that CBD can modulate the stress response, reducing amygdala activation.

Anxiolytic effects were observed mainly at higher doses, with the response being dependent on the individual and the formulation.

Experimental models suggest that CBD can protect neurons against oxidative stress and chronic inflammation.

The results are promising in the context of neurodegenerative diseases, but remain pre-clinical.

CBD has been shown to reduce inflammatory mediators (such as TNF-α, IL-6, and IL-1β) and inhibit the activation of the NF-κB pathway in cell and animal studies.

These effects are being explored in inflammatory bowel, skin, and joint pathologies.

In preclinical models, CBD reduced nerve hypersensitivity and inflammation.

Clinical evidence in humans is more consistent when CBD is used in combination with other cannabinoids, and remains limited when isolated.

Initial studies indicate that CBD can improve sleep quality, primarily indirectly, by reducing anxiety or discomfort.

It does not have a classic sedative profile.

In cancer cell lines, CBD has shown inhibition of tumour growth, induction of apoptosis and reduction of angiogenesis.

These results have been obtained exclusively in vitro or in animal models, without clinical validation.

Studies on human sebocytes indicate that CBD can regulate sebum production and reduce inflammatory cytokines, suggesting its potential in controlling acne and skin inflammation.